西安2022年2月3日 /美通社/ -- 西安天美生物科技股份有限公司(納斯達克代碼:BON)(“天美生物”或“公司”),一家在天然、健康和個人護理行業(yè)提供關鍵活性成分及解決方案的領先供應商,今天宣布其截至2021年9月30日的全年財務業(yè)績。
2021財年財務亮點
*本新聞稿末尾的附表包含財報的GAAP和非GAAP指標的調整。關于我們非GAAP指標的調整,請參見非GAAP財務指標的解釋。
管理層討論
“我們對公司業(yè)務的強勁需求的趨勢感到高興,并且對公司實現(xiàn)了兩位數(shù)的銷售增長和創(chuàng)下新高的收入感到自豪。這些結果充分的說明了我們強大的產(chǎn)品力、持續(xù)創(chuàng)新能力、以及我們作為客戶重要合作伙伴的價值。” 天美生物公司董事長兼CEO胡永衛(wèi)先生表示,“在短期內,因為全球疫情的久拖不決、全球貿易關系和宏觀經(jīng)融政策的變化,我們面臨著前所未有的全球供應鏈挑戰(zhàn)以及通貨膨脹相關的原材料和物流相關成本的增加,但我相信我們團隊完全有能力應對這些困境和壓力。并且我們將“轉為危機”,以此為契機推動公司的產(chǎn)品組合轉向更技術含量和更高利潤的產(chǎn)品系列,以增加我們的定價能力,獲取更高的利潤率;同時我們將提升優(yōu)化產(chǎn)能,并實施強而有力的成本控制措施。值得一提的是,我們以人體微生物為靶標的終端系列產(chǎn)品2021年取得了顯著進展,隨著我們全天然個人護理產(chǎn)品-羽淳的成功推出,以及水蘇糖益生菌粉等其他一系列產(chǎn)品陸續(xù)上市,在強大產(chǎn)品力和巨大市場需求的驅動下,我們對自己在終端用戶市場快速取得的進展有充分的信心。最后一點,隨著今年玉門工廠的完成投產(chǎn),將能帶來150%的收入增長,也使得我們能更高效地服務來自國內外的客戶,加速我們的全球業(yè)務擴張計劃,并為我們的投資者創(chuàng)造持久的長期價值?!?nbsp;
2021財年產(chǎn)品(按類別)與上年相比增長總結:
收入增加(減少) |
毛利潤增加(減少) |
|
香料原料 |
61.7% |
82.3% |
膳食補充劑(固體飲料) |
71.2% |
81.8% |
生物活性食品原料 |
(5.6%) |
(14.2%) |
香料原料
膳食補充劑(固體飲料)
生物活性食品原料
銷售費用從161,719美元減少到2021年同期的138,530美元,減少了23,189美元,或約14.3%。減少的原因是公司通過網(wǎng)絡營銷和銷售推廣,將重點轉向國內大型客戶,從而實現(xiàn)成本節(jié)約。
研究和開發(fā)費用從2020財年的205,359美元增長至249,050美元,增長了43,691美元,或約21.3%。增長的主要原因是研究材料的消耗增長了26,391美元以及研發(fā)測試和檢驗相關的費用增長了10,647美元。
政府補貼以補貼形式獲得并確認為其他營業(yè)收入,在截至2021年9月30日和2020年9月30日的財年里,總額分別為446,910美元和332,418美元。
凈利潤從截止至2020年9月30日財年的310萬美元增長至2021年同期的461萬美元。
經(jīng)營活動產(chǎn)生的凈現(xiàn)金在截止至2021年9月30日的財年期間為405萬美元,2020年同期為264萬美元。
每股基本收益(“EPS”)為0.69美元,2020年同期為0.58美元。
稀釋后每股收益(“EPS”)為0.68美元,2020年同期為0.58美元。
報告期后事件
投資者電話會議和網(wǎng)絡直播
討論公司2021年財年財務業(yè)績的網(wǎng)絡直播將于2022年2月3日美國東部時間上午9:00開始。網(wǎng)絡直播和相關PPT的獲取可以訪問公司的投資者網(wǎng)站 https://ir.bnlus.com/events-presentations/。對于無法觀看網(wǎng)絡直播的人,在活動結束后公司將在網(wǎng)站上提供錄制版本。
西安天美生物有限公司
西安天美生物專注于膳食營養(yǎng)補充劑的生物活性成分的生產(chǎn),如為食品制造商提供天然益生元;個人護理成分的生產(chǎn),如為香水香料制造商提供從植物來源的香料原料,天然復配膳食補充劑生產(chǎn),如固體飲料。欲了解更多信息,請訪問公司網(wǎng)站:www.bnlus.com.
安全港聲明
本新聞稿包含了1995年《私人證券訴訟改革法案》中的前瞻性聲明。前瞻性聲明包括了有關公司計劃、目標、戰(zhàn)略、未來事件或業(yè)績的聲明,以及其他假設和不包含歷史事件的聲明。當公司使用諸如“可能”、“將”、“打算”、“應該”、“相信”、“期望”、“預期”、“計劃”、“估計”等或其他類似的表達方式,并不與歷史事件有關,就是在做前瞻性聲明。前瞻性聲明不是對公司未來業(yè)績的保證,涉及風險和不確定性,可能會導致實際結果與前瞻性聲明中討論的公司預期有實質性的差異。這些陳述受不確定性和風險因素的印象,包括但不限于:公司的目標和戰(zhàn)略、公司的未來業(yè)務發(fā)展、公司產(chǎn)品和服務的需求、技術的變化、經(jīng)濟狀況、中國天然健康和個人護理行業(yè)的發(fā)展及公司希望發(fā)展的其他國際市場、聲譽和品牌、競爭和定價的影響、政府法規(guī)、中國及公司希望發(fā)展的其他國際市場的經(jīng)濟和商業(yè)狀況的變動,以及與上述任何情況相關的假設和公司提交給SEC報告中所陳述的其他風險。因此,我們提醒投資者不要過分依賴本新聞稿中的前瞻性陳述。公司向SEC提交的文件中討論了其他因素,這些文件可在www.sec.gov上查閱。公司不承擔公開修訂本聲明日期之后出現(xiàn)的事件或情況的前瞻性聲明的義務。
更多信息,請聯(lián)系:
In the United States: |
In China: |
Maggie Zhang | Impact IR |
Sophie Zhang | Impact IR |
Phone: (646) 893-8916 |
Email: sophie.zhang@irimpact.com |
Email: maggie.zhang@irimpact.com |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
September 30 |
||||||||
2021 |
2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS |
||||||||
Cash |
$ |
1,903,867 |
$ |
53,106 |
||||
Short-term investments |
1,703,314 |
- |
||||||
Accounts receivable, net |
6,152,807 |
5,771,008 |
||||||
Inventories, net |
1,596,492 |
1,016,442 |
||||||
Advance to suppliers, net |
4,094,312 |
3,491,145 |
||||||
Deferred initial public offering costs |
- |
510,079 |
||||||
Acquisition deposit |
1,000,000 |
- |
||||||
Prepaid expenses and other current assets |
98,960 |
7,434 |
||||||
TOTAL CURRENT ASSETS |
16,549,752 |
10,840,214 |
||||||
Property, plant and equipment, net |
19,228,642 |
14,171,963 |
||||||
Intangible assets, net |
411,056 |
140,993 |
||||||
Right-of-use lease assets, net |
201,007 |
- |
||||||
Deferred tax assets, net |
22,342 |
49,059 |
||||||
TOTAL ASSETS |
$ |
36,412,799 |
$ |
25,202,229 |
||||
LIABILITIES AND EQUITY |
||||||||
CURRENT LIABILITIES |
||||||||
Short-term loans |
$ |
41,381 |
$ |
1,289,081 |
||||
Current portion of long-term loans |
448,005 |
1,227,346 |
||||||
Third party loans |
- |
690,327 |
||||||
Accounts payable |
380,385 |
1,288,629 |
||||||
Due to related parties |
245,104 |
2,322,990 |
||||||
Taxes payable |
5,052,018 |
4,402,625 |
||||||
Deferred revenue |
1,096,101 |
385,978 |
||||||
Accrued expenses and other current liabilities |
41,711 |
56,604 |
||||||
Finance lease liabilities, current |
161,286 |
33,389 |
||||||
Operating lease liability, current |
62,871 |
- |
||||||
TOTAL CURRENT LIABILITIES |
$ |
7,528,862 |
$ |
11,696,969 |
||||
Long-term loans |
2,173,532 |
2,482,251 |
||||||
Finance lease liabilities, noncurrent |
28,953 |
- |
||||||
Operating lease liability, noncurrent |
146,703 |
- |
||||||
TOTAL LIABILITIES |
9,878,050 |
14,179,220 |
||||||
COMMITMENTS AND CONTINGENCIES |
- |
- |
||||||
EQUITY |
||||||||
Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 8,330,000 and 5,800,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively |
$ |
833 |
$ |
580 |
||||
Additional paid in capital |
15,540,433 |
5,251,205 |
||||||
Statutory reserve |
1,050,721 |
579,922 |
||||||
Retained earnings |
9,192,676 |
5,072,672 |
||||||
Accumulated other comprehensive income (loss) |
222,221 |
(388,102) |
||||||
TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY |
26,006,884 |
10,516,277 |
||||||
Non-controlling interest |
527,865 |
506,732 |
||||||
Total equity |
26,534,749 |
11,023,009 |
||||||
TOTAL LIABILITIES AND EQUITY |
$ |
36,412,799 |
$ |
25,202,229 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
For the Years Ended September 30, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
REVENUE |
$ |
25,494,564 |
$ |
18,219,959 |
$ |
16,396,018 |
||||||
COST OF REVENUE |
(18,382,637) |
(13,017,646) |
(11,113,922) |
|||||||||
GROSS PROFIT |
7,111,927 |
5,202,313 |
5,282,096 |
|||||||||
OPERATING EXPENSES |
||||||||||||
Selling expenses |
(138,530) |
(161,719) |
(273,841) |
|||||||||
General and administrative expenses |
(1,323,726) |
(1,367,070) |
(1,310,215) |
|||||||||
Research and development expenses |
(249,050) |
(205,359) |
(522,867) |
|||||||||
Total operating expenses |
(1,711,306) |
(1,734,148) |
(2,106,923) |
|||||||||
INCOME FROM OPERATIONS |
5,400,621 |
3,468,165 |
3,175,173 |
|||||||||
OTHER INCOME (EXPENSES) |
||||||||||||
Interest income |
3,207 |
714 |
2,271 |
|||||||||
Interest expense |
(417,266) |
(329,102) |
(333,190) |
|||||||||
Unrealized foreign transaction exchange gain (loss) |
(45,124) |
(248) |
5,281 |
|||||||||
Gain on disposal of fixed assets |
- |
20,150 |
- |
|||||||||
Government subsidies |
449,972 |
362,187 |
140,295 |
|||||||||
Income from short-term investments |
565 |
- |
- |
|||||||||
Other income |
38,409 |
132,713 |
- |
|||||||||
Total other income (expenses), net |
29,763 |
186,414 |
(185,343) |
|||||||||
INCOME BEFORE INCOME TAX PROVISION |
5,430,384 |
3,654,579 |
2,989,830 |
|||||||||
INCOME TAX PROVISION |
(820,931) |
(556,262) |
(427,194) |
|||||||||
NET INCOME |
4,609,453 |
3,098,317 |
2,562,636 |
|||||||||
Less: net income (loss) attributable to non-controlling interest |
18,650 |
71,644 |
(11,167) |
|||||||||
NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED |
$ |
4,590,803 |
$ |
3,026,673 |
$ |
2,573,803 |
||||||
OTHER COMPREHENSIVE INCOME (LOSS) |
||||||||||||
Total foreign currency translation adjustment |
612,806 |
450,234 |
(281,699) |
|||||||||
TOTAL COMPREHENSIVE INCOME |
5,222,259 |
3,548,551 |
2,280,937 |
|||||||||
Less: comprehensive income (loss) attributable to non-controlling interest |
21,133 |
81,737 |
(10,969) |
|||||||||
COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED |
$ |
5,201,126 |
$ |
3,466,814 |
$ |
2,291,906 |
||||||
EARNINGS PER SHARE |
||||||||||||
Basic |
$ |
0.69 |
$ |
0.58 |
$ |
0.50 |
||||||
Diluted |
$ |
0.68 |
$ |
0.58 |
$ |
0.50 |
||||||
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING |
||||||||||||
Basic |
6,615,833 |
5,210,649 |
5,166,667 |
|||||||||
Diluted |
6,706,235 |
5,210,649 |
5,166,667 |
BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Years Ended September 30, |
||||||||||||
2021 |
2020 |
2019 |
||||||||||
Cash flows from operating activities |
||||||||||||
Net income |
$ |
4,609,453 |
$ |
3,098,317 |
$ |
2,562,636 |
||||||
Adjustments to reconcile net income to cash provided by operating activities |
||||||||||||
Allowance for doubtful accounts |
2,948 |
22,137 |
34,328 |
|||||||||
Depreciation and amortization |
228,547 |
230,597 |
226,633 |
|||||||||
Inventory reserve (recovery) |
(312,532) |
29,539 |
- |
|||||||||
Deferred income tax |
29,109 |
(7,751) |
(5,149) |
|||||||||
Amortization of operating lease right-of-use assets |
58,147 |
- |
||||||||||
Amortization of stock options |
44,910 |
- |
- |
|||||||||
Unrealized foreign currency exchange loss (gain) |
45,124 |
248 |
(5,281) |
|||||||||
Gain on disposal of property and equipment |
- |
(20,150) |
- |
|||||||||
Changes in operating assets and liabilities: |
||||||||||||
Accounts receivable |
(89,543) |
(284,546) |
(2,912,222) |
|||||||||
Inventories |
(209,011) |
1,636,321 |
6,681,972 |
|||||||||
Advance to suppliers, net |
(399,262) |
(3,021,739) |
168,868 |
|||||||||
Prepaid expenses and other current assets |
2,642 |
72,116 |
173,609 |
|||||||||
Accounts payable |
(969,414) |
(1,982,205) |
(78,356) |
|||||||||
Operating lease liabilities |
(49,648) |
- |
- |
|||||||||
Taxes payable |
410,716 |
2,662,542 |
1,538,662 |
|||||||||
Deferred revenue |
684,030 |
161,045 |
(1,223,824) |
|||||||||
Accrued expenses and other current liabilities |
(33,092) |
46,605 |
(57,053) |
|||||||||
Net cash provided by operating activities |
4,053,124 |
2,643,076 |
7,104,823 |
|||||||||
Cash flows from investing activities |
||||||||||||
Purchase of short-term investments |
(2,159,920) |
- |
- |
|||||||||
Proceeds upon redemption of short-term investments |
470,082 |
- |
- |
|||||||||
Purchase of property and equipment |
(51,878) |
(31,885) |
(213,634) |
|||||||||
Capital expenditures on construction-in-progress |
(4,432,941) |
(4,301,103) |
(6,861,257) |
|||||||||
Purchase of intangible assets |
(269,088) |
- |
- |
|||||||||
Refund (payment) of acquisition deposit |
(1,000,000) |
1,329,945 |
(1,355,067) |
|||||||||
Net cash used in investing activities |
(7,443,745) |
(3,003,043) |
(8,429,958) |
|||||||||
Cash flows from financing activities |
||||||||||||
Net proceeds from issuance of Ordinary Shares in initial public offerings |
11,271,480 |
- |
- |
|||||||||
Proceeds from short-term loans |
1,257,225 |
2,033,570 |
4,008,293 |
|||||||||
Proceeds from long-term loans |
1,245,871 |
319,342 |
- |
|||||||||
Repayment of short-term loans |
(2,563,433) |
(2,872,778) |
(4,514,482) |
|||||||||
Repayment of long-term loans |
(2,522,101) |
- |
- |
|||||||||
Proceeds from (repayment of) borrowings from related parties |
(2,262,378) |
1,067,808 |
543,976 |
|||||||||
Proceeds from (repayment of) third party loans |
(721,484) |
238,133 |
(101,793) |
|||||||||
Principal payment from (repayment of) finance lease |
169,153 |
(392,030) |
432,722 |
|||||||||
Capital contribution from non-controlling interest |
- |
- |
435,964 |
|||||||||
Payment for deferred initial public offering costs |
(521,651) |
(281,553) |
- |
|||||||||
Net cash provided by financing activities |
5,352,682 |
112,492 |
804,680 |
|||||||||
Effect of changes of foreign exchange rates on cash |
(111,300) |
6,810 |
(6,630) |
|||||||||
Net increase (decrease) in cash |
1,850,761 |
(240,665) |
(527,085) |
|||||||||
Cash, beginning of year |
53,106 |
293,771 |
820,856 |
|||||||||
Cash, end of year |
$ |
1,903,867 |
$ |
53,106 |
$ |
293,771 |
||||||
Supplemental disclosure of cash flow information |
||||||||||||
Cash paid for interest expense |
$ |
417,266 |
$ |
276,671 |
$ |
333,190 |
||||||
Cash paid for income tax |
$ |
2,411 |
$ |
- |
$ |
115,179 |
||||||
Supplemental disclosure of non-cash investing and financing activities |
||||||||||||
Amortization of share-based compensation for initial public offering services |
$ |
422,221 |
$ |
211,112 |
$ |
- |
||||||
Right-of-use assets obtained in exchange for operating lease obligations |
$ |
257,564 |
$ |
- |
$ |
- |
Bon Natural Life Limited
GAAP to Non-GAAP Reconciliation
The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.
Reconciliation of Adjusted EBITDA to Net Income |
|||||
30-Sep |
|||||
2021 |
2020 |
||||
Net income |
$ |
4,609,453 |
$ |
3,098,317 |
|
Interest expense |
417,266 |
329,102 |
|||
Income taxes |
820,931 |
556,262 |
|||
Depreciation and amortization |
228,547 |
230,597 |
|||
Non-cash item(1) |
44,910 |
- |
|||
Adjusted EBITDA |
$ |
6,121,107 |
$ |
4,214,278 |
(1) Non-cash item represents adjustment of stock-based compensation to reconcile net income to net cash provided by operations as presented on the Statement of Cash Flows